两种药物在表浅性膀胱癌术后灌注的疗效及经济性分析

Efficacy and cost-effectiveness of two drugs in postoperative perfusion for superficial bladder cancer

目的探讨羟基喜树碱与吡柔比星在表浅性膀胱癌术后灌注的疗效及经济性分析。方法回顾性分析经尿道膀胱癌切除术的123例表浅性膀胱癌患者临床资料,两组均行经尿道膀胱癌切除术,术后1 w开始行膀胱内灌注化疗,根据化疗药物的不同分为羟基喜树碱组与吡柔比星组,对比两组术后1年的治疗有效率、不良反应及成本-效果比。结果两组的治疗有效率和不良反应发生率比较无统计学差异(P>0.05),但羟基喜树碱组的成本-效果比明显低于吡柔比星组(P<0.05)。结论羟基喜树碱对表浅性膀胱癌术后灌注化疗的疗效与吡柔比星相当,但羟基喜树碱更为经济。

Objective To explore the efficacy and cost-effectiveness of hydroxycamptotheein and pirarubicin in postoperative peffusion for superficial bladder cancer. Methods The clinical data of 123 patients with superficial bladder cancer treated with transurethral bladder cancer resection were retrospectively analyzed. These patients were divided into a hydroxyeamptotheein group and a pirarubiein group according to different chemotherapy drugs. The two groups were treated with transurethral bladder cancer resection. One week after the operation, intravesieal infusion chemotherapy was carried out. The efficiency, adverse reactions and cost-effectiveness ratio one year after the operation between the two groups were compared. Results The curative effects and incidences of adverse reactions showed no statistical difference between the two groups （P 〉 0.05）, but the cost-effectiveness ratio in the hydroxyeamptotheein group was much lower than that in the pirarubiein group （P 〈 0.05）. Conclusion The efficacy of hydroxyeamptotheein in the postoperative infusion chemotherapy for superficial bladder cancer was equivalent to that of pirarubiein, but hydroxyeamptotheein is more cost-effective.